Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections
Latest Information Update: 03 Mar 2020
At a glance
- Drugs Cefiderocol (Primary)
- Indications Bacterial infections; Gram-negative infections
- Focus Expanded access; Therapeutic Use
- Sponsors Shionogi
Most Recent Events
- 25 Feb 2020 Status changed from recruiting to completed.
- 31 Dec 2018 New trial record